戻る
Syndax Pharmaceuticals Gains on Strong Revuforj Sales and Regulatory Progress
戻る
株式ニュース
テーマ
Syndax Pharmaceuticals Gains on Strong Revuforj Sales and Regulatory Progress
Syndax Pharmaceuticals Gains on Strong Revuforj Sales and Regulatory Progress
Edgen Stock
·
Sep 13 2025, 22:02
共有先
共有先
リンクをコピー
ソース：
[1] Syndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRC
[2] Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update
[3] Stifel resumes Syndax Pharmaceuticals stock coverage with Buy rating - Investing.com
Edgen Stock·Sep 13 2025, 22:02Edgen Stock·Sep 13 2025, 22:02
Edgen Stock·Sep 13 2025, 22:02